Siemens Healthineers Opens Innovation Center in Erlangen

Siemens HealthineersSiemens Healthineers has opened its new Innovation Center in Erlangen, Germany, in the heart of the regional medical technology research area known as Medical Valley. The focus is on open innovation by collaborating with external partner companies, start-ups and academic and clinical institutions to improve healthcare worldwide. The innovation center complements an existing ecosystem of centers in Shanghai, China, and Bengaluru, India. The underpinning idea is to create an infrastructure to strengthen innovation across the region, promote open collaboration in research, development and production, and enable customer- and market-oriented development.

"With our new Innovation Center, we are highlighting our commitment to the Erlangen and Forchheim locations and continuing to consistently implement our strategy of an open innovation culture," said Peter Schardt, Chief Technology Officer (CTO) of Siemens Healthineers. "The goal is to jointly focus on new technologies and value-added processes that have the potential to disrupt the healthcare system for the benefit of patients. By promoting open collaborations and projects, Siemens Healthineers and its customers will enable more people around the world to access high-quality medical care - from precise diagnosis to the right therapy."

Among other things, the company’s ASOR community has a co-working space in the new premises to further advance research and development for extended reality applications with internal and external partner companies, and to make digital content more tangible. Specifically, the aim is to test and develop prototypes and to virtually simulate medical technology solutions and applications, for example for training.

The Innovation Center is also home to partnerships such as the digital health innovation platform d.hip, an alliance of industry, university medicine and research organizations which aims to advance the digitization of the healthcare system.

In fiscal 2022 Siemens Healthineers invested around €1.8 billion in research and development and holds around 23,000 technical property rights, including around 15,000 granted patents.

About Siemens Healthineers

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies are continuously developing their product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers' ability to provide high-quality, efficient care. In fiscal 2022, which ended on September 30, 2022, Siemens Healthineers, which has approximately 69,500 employees worldwide, generated revenue of around €21.7 billion and adjusted EBIT of almost €3.7 billion.

Most Popular Now

AI System Helps Doctors Identify Patient…

A new study from Vanderbilt University Medical Center shows that clinical alerts driven by artificial intelligence (AI) can help doctors identify patients at risk for suicide, potentially improving prevention efforts...

Smartphone App can Help Reduce Opioid Us…

Patients with opioid use disorder can reduce their days of opioid use and stay in treatment longer when using a smartphone app as supportive therapy in combination with medication, a...

AI's New Move: Transforming Skin Ca…

Pioneering research has unveiled a powerful new tool in the fight against skin cancer, combining cutting-edge artificial intelligence (AI) with deep learning to enhance the precision of skin lesion classification...

Leveraging AI to Assist Clinicians with …

Physical examinations are important diagnostic tools that can reveal critical insights into a patient's health, but complex conditions may be overlooked if a clinician lacks specialized training in that area...

AI can Improve Ovarian Cancer Diagnoses

A new international study led by researchers at Karolinska Institutet in Sweden shows that AI-based models can outperform human experts at identifying ovarian cancer in ultrasound images. The study is...

Predicting the Progression of Autoimmune…

Autoimmune diseases, where the immune system mistakenly attacks the body's own healthy cells and tissues, often have a preclinical stage before diagnosis that’s characterized by mild symptoms or certain antibodies...

Major EU Project to Investigate Societal…

A new €3 million EU research project led by University College Dublin (UCD) Centre for Digital Policy will explore the benefits and risks of Artificial Intelligence (AI) from a societal...

Using AI to Uncover Hospital Patients�…

Across the United States, no hospital is the same. Equipment, staffing, technical capabilities, and patient populations can all differ. So, while the profiles developed for people with common conditions may...

New AI Tool Uses Routine Blood Tests to …

Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will benefit from immune checkpoint inhibitors - a type of...

New Method Tracks the 'Learning Cur…

Introducing Annotatability - a powerful new framework to address a major challenge in biological research by examining how artificial neural networks learn to label genomic data. Genomic datasets often contain...

From Text to Structured Information Secu…

Artificial intelligence (AI) and above all large language models (LLMs), which also form the basis for ChatGPT, are increasingly in demand in hospitals. However, patient data must always be protected...

AI Innovation Unlocks Non-Surgical Way t…

Researchers have developed an artificial intelligence (AI) model to detect the spread of metastatic brain cancer using MRI scans, offering insights into patients’ cancer without aggressive surgery. The proof-of-concept study, co-led...